Standout Papers

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial 2024 202639
  1. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial (2024)
    Howard A. Burris, Takuji Okusaka et al. The Lancet Oncology

Citation Impact

3 from Science/Nature 56 standout
Sub-graph 1 of 23

Citing Papers

Endogenous stimuli-responsive separating microneedles to inhibit hypertrophic scar through remodeling the pathological microenvironment
2024 Standout
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
2024 Standout
1 intermediate paper

Works of Junhe Li being referenced

Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro
2013

Author Peers

Author Molecular Biology Cancer Research Oncology Last Decade Papers Cites
Junhe Li 546 338 162 31 763
Esmaeil Farzaneh 32 12 38 55 499
H Sievänen 64 63 11 1.4k
Tavarekere K. Chandrashekar 1004 4 117 108 3.6k
Duncan A Grant 13 261
Corinna Stumm 2 17 302

All Works

Loading papers...

Rankless by CCL
2026